Q-omics provides the consensus-scored TBC1D3L profile across patient tissues and cancer cell-line models. TBC1D3L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D3L is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, TBC1D3L RNA expression shows 15,633 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where TBC1D3L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D3L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D3L survival associations across molecular data types. TBC1D3L RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D3L RNA expression–survival associations across cancer types. High TBC1D3L expression shows unfavorable associations in KIRC, ACC, LIHC and PRAD, but favorable associations in BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D3L RNA expression.
This table summarizes TBC1D3L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D3L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D3L shows higher tumor expression in KIRC, CHOL, LIHC, THCA, STAD and KIRP. The KIRC box plot shows higher TBC1D3L RNA expression in tumor versus normal tissue (log2 FC = +0.268, t-test p < 0.001).
This table shows molecular features associated with TBC1D3L in patient tissues and cancer cell lines. In patient samples, TBC1D3L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D3L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Myeloma.
